Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy
2025 · Cell stem cell · 13 citations
https://doi.org/10.1016/j.stem.2025.05.007
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
37
Papers
349
Citations
9
h-index
9
i10-index
Soheila Shirinbak is an academic researcher from Fate Therapeutics (United States). The author has contributed to research in topics: CAR-T cell therapy research & Asthma and respiratory diseases & Immune Cell Function and Interaction. The author has an h-index of 9, co-authored 32 publications.
https://doi.org/10.1016/j.stem.2025.05.007
https://doi.org/10.1016/j.xcrm.2025.102195
Click to start Chat